A Bakery Square startup company that matches cancer patients with clinical trials has been acquired by a California outfit.
Realyze Intelligence Inc., a UPMC Enterprises portfolio company, has been acquired by Carta Healthcare in San Francisco, the company announced Monday. Realyze was formed in 2020 by CEO and serial entrepreneur Aaron Brauser and pathologist Gilan El Saadawi, who is chief medical officer.
Mr. Brauser and Dr. El Saadawi are veterans of M*Modal, a former Squirrel Hill-based medical transcription service that was acquired by St. Paul, Minn.-based 3M for $1 billion in 2018.
Terms of the Realyze deal were not disclosed.
In February, Realyze employed 12 people and generated $3.4 million in investment capital. During the same month, it was also included in the inaugural class of companies in the CancerX Startup Accelerator, part of President Joe Biden’s push to halve the U.S. cancer death rate within 25 years.
“We are inspired by Realyze Intelligence’s shared ability to use clinician-trained AI and a human-in-the-loop approach to maximize insights from clinical data for clinical trials and cancer registries,” Carta Healthcare CEO Brent Dover said in a prepared statement.
Read More
In an internal analysis, Realyze Intelligence found that the UPMC Hillman Cancer Center saw seven times more patients matched to clinical trials and twice as many enrolled when compared to the same time frame without the company’s software. Two million people are diagnosed with cancer in the U.S. every year, but only 5% to 6% of patients make it into a clinical trial, according to the company.
Clinical trials are key in the development of new therapies.
Realyze is the third company to exit UPMC Enterprises this year, the hospital and health insurance giant’s venture capital and commercialization arm. The other two exits were Signallamp, a remote chronic care management outfit, and UPMC’s teleconsult technology platform.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.